<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We studied a model of in vivo purging with Rituximab and high-dose (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e>) <z:chebi fb="0" ids="28680">cytarabine</z:chebi> in 14 patients with relapsed/refractory follicular <z:hpo ids='HP_0002665'>lymphoma</z:hpo> and two with refractory mantle cell <z:hpo ids='HP_0002665'>lymphoma</z:hpo> enrolled in a program of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> chemotherapy and autotransplant </plain></SENT>
<SENT sid="1" pm="."><plain>After two courses of debulking immunochemotherapy with Rituximab, <z:chebi fb="0" ids="28445">Vincristine</z:chebi> and <z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi>, we used a combination of Rituximab, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> <z:chebi fb="0" ids="28680">cytarabine</z:chebi> and granulocyte colony-stimulating factor for peripheral blood stem cells (PBSC) mobilization </plain></SENT>
<SENT sid="2" pm="."><plain>The median number of CD34+ cells collected was 14.69 x 10(6)/kg (range 5.74-73.2) </plain></SENT>
<SENT sid="3" pm="."><plain>Monitoring of peripheral CD19+ and CD20+ B cells prior to and throughout the purging period showed that a treatment with Rituximab, <z:chebi fb="0" ids="28445">Vincristine</z:chebi> and <z:chebi fb="0" ids="4027">Cyclophosphamide</z:chebi> results in a profound <z:mpath ids='MPATH_63'>depletion</z:mpath> of B cells in peripheral blood </plain></SENT>
<SENT sid="4" pm="."><plain>B-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> persists during mobilization with Rituximab and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> <z:chebi fb="0" ids="28680">cytarabine</z:chebi> allowing a collection of PBSC free of B cells (median CD19+ and CD20+ cells counts 0%) </plain></SENT>
<SENT sid="5" pm="."><plain>Of nine patients PCR positive for bcl-2 or bcl-1 in blood and marrow at the start of immunochemotherapy, <z:hpo ids='HP_0000001'>all</z:hpo> showed PCR-negative PBSC </plain></SENT>
<SENT sid="6" pm="."><plain>In conclusion, in patients with indolent <z:hpo ids='HP_0002665'>lymphoma</z:hpo>, the concurrent administration of Rituximab and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">HD</z:e> <z:chebi fb="0" ids="28680">cytarabine</z:chebi> is a safe and efficient method to obtain in vivo purged PBSC </plain></SENT>
<SENT sid="7" pm="."><plain>Immunochemotherapy prior to mobilization produces B-cell <z:mpath ids='MPATH_63'>depletion</z:mpath> and seems to be a useful preparative step </plain></SENT>
</text></document>